OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
5
Results
Show all
Save search
Copy query
Show results for
Unknown
(5)
Release Date
2018
(1)
2017
(1)
2016
(1)
2015
(1)
2012
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Not available
S-EPMC5019749
|
biostudies-literature
Cite
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Not available
S-EPMC6075855
|
biostudies-literature
Cite
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Not available
S-EPMC3646316
|
biostudies-literature
Cite
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
Not available
S-EPMC4879713
|
biostudies-literature
Cite
Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma.
Not available
S-EPMC6369924
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets